Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Re-introducing whole blood for transfusion: considerations for blood providers

TA. Hervig, HA. Doughty, RA. Cardigan, TO. Apelseth, JR. Hess, F. Noorman, M. Bohoněk, MH. Yazer, J. Lu, S. Wendel, RL. Sparrow, Biomedical Excellence for Safer Transfusion Collaborative

. 2021 ; 116 (2) : 167-174. [pub] 20200930

Language English Country Great Britain

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc21019391

Whole blood is the original blood preparation but disappeared from the blood bank inventories in the 1980s following the advent of component therapy. In the early 2000s, both military and civilian practice called for changes in the transfusion support for massive haemorrhage. The 'clear fluid' policy was abandoned and replaced by early balanced transfusion of platelets, plasma and red cells. Whole blood is an attractive alternative to multi-component therapy, which offers reduced hemodilution, lower donor exposure and simplified logistics. However, the potential for wider re-introduction of whole blood requires re-evaluation of haemolysins, storage conditions and shelf-life, the need for leucocyte depletion/ pathogen reduction and inventory management for blood providers. This review addresses these questions and calls for research to define the optimal whole blood product and the indications for its use.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21019391
003      
CZ-PrNML
005      
20231221120247.0
007      
ta
008      
210728s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/vox.12998 $2 doi
035    __
$a (PubMed)32996604
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Hervig, Tor A $u Blood Bank, Haugesund hospital, Haugesund, Norway
245    10
$a Re-introducing whole blood for transfusion: considerations for blood providers / $c TA. Hervig, HA. Doughty, RA. Cardigan, TO. Apelseth, JR. Hess, F. Noorman, M. Bohoněk, MH. Yazer, J. Lu, S. Wendel, RL. Sparrow, Biomedical Excellence for Safer Transfusion Collaborative
520    9_
$a Whole blood is the original blood preparation but disappeared from the blood bank inventories in the 1980s following the advent of component therapy. In the early 2000s, both military and civilian practice called for changes in the transfusion support for massive haemorrhage. The 'clear fluid' policy was abandoned and replaced by early balanced transfusion of platelets, plasma and red cells. Whole blood is an attractive alternative to multi-component therapy, which offers reduced hemodilution, lower donor exposure and simplified logistics. However, the potential for wider re-introduction of whole blood requires re-evaluation of haemolysins, storage conditions and shelf-life, the need for leucocyte depletion/ pathogen reduction and inventory management for blood providers. This review addresses these questions and calls for research to define the optimal whole blood product and the indications for its use.
650    12
$a krevní transfuze $7 D001803
650    _2
$a lidé $7 D006801
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Doughty, Heidi A $u Medical, NHS Blood and Transplant, Birmingham, UK
700    1_
$a Cardigan, Rebecca A $u Component Development, NHS Blood & Transplant, Cambridge, UK
700    1_
$a Apelseth, Torunn O $u Department of Immunology and Transfusion Medicine, Haukeland University Hospital, Bergen, Norway
700    1_
$a Hess, John R. $u Laboratory Medicine, University of Washington, Seattle, WA, USA $7 xx0311953
700    1_
$a Noorman, Femke $u Quality, Research and Development, Military Blood Bank, Leiden, Netherlands
700    1_
$a Bohoněk, Miloš $u Hematology, Biochemistry and Blood Transfusion, Central Military Hospital Prague, Prague, Czech Republic
700    1_
$a Yazer, Mark H $u Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA
700    1_
$a Lu, Jia $u Defence Medical & Environmental Research Institute, DSO National Laboratories (Kent Ridge), Singapore City, Singapore
700    1_
$a Wendel, Silvano $u Blood Bank, Hospital Sirio Libanes, São Paulo, Brazil
700    1_
$a Sparrow, Rosemary L $u Epidemiology and Preventive Medicine, Monash University, Melbourne, Vic, Australia
710    2_
$a Biomedical Excellence for Safer Transfusion Collaborative
773    0_
$w MED00010756 $t Vox sanguinis $x 1423-0410 $g Roč. 116, č. 2 (2021), s. 167-174
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32996604 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20231221120242 $b ABA008
999    __
$a ok $b bmc $g 1690255 $s 1139837
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 116 $c 2 $d 167-174 $e 20200930 $i 1423-0410 $m Vox sanguinis $n Vox Sang $x MED00010756
LZP    __
$a Pubmed-20210728

Find record

Citation metrics

Archiving options